# Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year

> **NCT04455958** · PHASE2 · WITHDRAWN · sponsor: **OHSU Knight Cancer Institute**

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Symptomatic COVID-19 Infection Laboratory-Confirmed

## Interventions

- **DRUG:** Lopinavir/Ritonavir
- **DRUG:** Placebo Administration
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04455958
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-05-01
- **Primary completion:** 2021-11-01
- **Final completion:** 2021-11-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** limited resources
- **Last updated:** 2021-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04455958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04455958, "Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04455958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*